JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`1
`
`·1
`
`·2
`
`·3
`
`·4
`
`·5· · UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·6
`· · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`·7
`
`·8· · · · · · MYLAN PHARMACEUTICALS INC.,
`
`·9· · · · · · · · · ·Petitioner,
`
`10· · · · · · · · · · · · V.
`
`11· · · · · · · · · BIOGEN MA INC.,
`
`12· · · · · · · · · Patent Owner.
`· · ·____________________________________________
`13· · · · · · · · · ·IPR2018-01403
`
`14· · · · · · · ·Patent No. 8,399,514
`· · ·____________________________________________
`15
`· · · · PATENT OWNER’S NOTICE OF DEPOSITION OF
`16· · · · · · · · · JENNIFER ROCK
`
`17
`· · · · · · · · ·Taken on May 2, 2019
`18
`
`19
`
`20
`
`21
`
`22
`· · · · · · ·Reported by Jonna J. Schrupp
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 1
`
`
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`1
`
`·1
`
`·2
`
`·3
`
`·4
`
`·5· · UNITED STATES PATENT AND TRADEMARK OFFICE
`
`·6
`· · · ·BEFORE THE PATENT TRIAL AND APPEAL BOARD
`·7
`
`·8· · · · · · MYLAN PHARMACEUTICALS INC.,
`
`·9· · · · · · · · · ·Petitioner,
`
`10· · · · · · · · · · · · V.
`
`11· · · · · · · · · BIOGEN MA INC.,
`
`12· · · · · · · · · Patent Owner.
`· · ·____________________________________________
`13· · · · · · · · · ·IPR2018-01403
`
`14· · · · · · · ·Patent No. 8,399,514
`· · ·____________________________________________
`15
`· · · · PATENT OWNER’S NOTICE OF DEPOSITION OF
`16· · · · · · · · · JENNIFER ROCK
`
`17
`· · · · · · · · ·Taken on May 2, 2019
`18
`
`19
`
`20
`
`21
`
`22
`· · · · · · ·Reported by Jonna J. Schrupp
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 1
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`2
`
`·1· · · · · · ·DEPOSITION OF JENNIFER ROCK, taken
`
`·2· ·pursuant to Notice and Agreement under the Rules of
`
`·3· ·Civil Procedure for the District Courts of
`
`·4· ·Minnesota, and taken at Thomson Reuters, 610
`
`·5· ·Opperman Drive, Eagan, Minnesota, and taken on the
`
`·6· ·2nd day of May, 2019, before Jonna Schrupp, a Notary
`
`·7· ·Public in and for the County of Hennepin, State of
`
`·8· ·Minnesota, commencing at 3:00 p.m.
`
`·9
`
`10· · · · · · · · · · · ·APPEARANCES
`
`11
`
`12· · · · · · ·Mark J. Feldstein and Michael R. Galgano,
`
`13· ·Attorneys at Law, FINNEGAN, HENDERSON, FARABOW,
`
`14· ·GARRETT & DUNNER, LLP, 901 New York Avenue, NW,
`
`15· ·Washington, DC 20001-4413, appeared on behalf of the
`
`16· ·Patent Owner.
`
`17· · · · · · ·Emily J. Greb, Attorney at Law, PERKINS
`
`18· ·COIE, 33 East Main Street, Suite 201, Madison,
`
`19· ·Wisconsin 53703, appeared on behalf of the
`
`20· ·Petitioner.
`
`21· · · · · · ·Susan E. Ellingstad, Attorney at Law,
`
`22· ·LOCKRIDGE GRINDAL NAUEN, PLLP, 100 Washington Avenue
`
`23· ·South, Suite 200, Minneapolis, Minnesota 55401,
`
`24· ·appeared on behalf of Jennifer Rock.
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.com
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 2
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`3
`
`·1· · · · · · · · · · · · I N D E X
`
`·2
`
`·3· ·EXAMINATION OF WITNESS:· · · · · · · · ·PAGE
`
`·4
`
`·5· ·Mr. Feldstein· · · · · · · · · · · · · · ·4, 38
`
`·6· ·Ms. Greb· · · · · · · · · · · · · · · · ·36
`
`·7
`
`·8· ·OBJECTION BY:
`
`·9
`
`10· ·Ms. Greb· · · · · · · · · · · 6, 7, 8, 9, 10, 13,
`· · · · · · · · · · · · · · · · · ·14, 15, 16, 17, 18,
`11· · · · · · · · · · · · · · · · ·19, 20, 21, 22, 23,
`· · · · · · · · · · · · · · · · · ·24, 25, 26, 27, 31,
`12· · · · · · · · · · · · · · · · ·32, 33, 34
`
`13· ·Mr. Feldstein· · · · · · · · · · · · · · 37
`
`14
`
`15· ·DEPOSITION EXHIBITS
`
`16
`
`17· ·Exhibit 2057, marked· · · · · · · · · · ·29
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 3
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`4
`
`·1· · · · · · · · · · · ·P R O C E E D I N G S
`
`·2
`
`·3· · · · · · · · · · · · · ·JENNIFER ROCK,
`
`·4· · · · after having been first duly sworn, was examined and
`
`·5· · · · testified as follows:
`
`·6· · · · · · · · · · · · · · EXAMINATION
`
`·7· ·BY MR. FELDSTEIN:
`
`·8· ·Q· · Good afternoon, Ms. Rock.· How are you?
`
`·9· ·A· · Good.· How are you?
`
`10· ·Q· · Good.· As I mentioned, I'm Mark Feldstein, I'm from
`
`11· · · · Finnegan and Henderson representing the patent oWner
`
`12· · · · in this case, Biogen.
`
`13· ·A· · Okay.
`
`14· ·Q· · I just want to give you a couple documents so that
`
`15· · · · you have them.· I'm going to give you things, and
`
`16· · · · they're all marked with exhibit numbers, so I don't
`
`17· · · · know if you've seen them like this.· This is Exhibit
`
`18· · · · 1055, exhibit 1005, and then Exhibit 1016 and
`
`19· · · · lastly, for now, Exhibit 1026.· I don't have any
`
`20· · · · immediate questions about 1005, 1016, 1026, I just
`
`21· · · · wanted you to have them.
`
`22· ·A· · Okay.
`
`23· ·Q· · Just as background, Ms. Rock, have you been deposed
`
`24· · · · before?
`
`25· ·A· · No, I have not.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 4
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`5
`
`·1· ·Q· · Have you prepared declarations similar to Exhibit
`
`·2· · · · 1055 before?
`
`·3· ·A· · Yes.
`
`·4· ·Q· · For roughly how many times?
`
`·5· ·A· · I can say two other times besides this.
`
`·6· ·Q· · About when were those?
`
`·7· ·A· · Within the last three years.· I don't have the exact
`
`·8· · · · dates.
`
`·9· ·Q· · Can you tell me, Ms. Rock, what you did, if
`
`10· · · · anything, to prepare for your deposition today?
`
`11· ·A· · I met with legal counsel and basically had a look at
`
`12· · · · these documents.
`
`13· ·Q· · You met with which legal counsel?
`
`14· ·A· · Both.
`
`15· ·Q· · And did you have discussions with Ms. Greb here,
`
`16· · · · plaintiff's counsel?
`
`17· ·A· · Yes.
`
`18· ·Q· · What discussions did you have with Ms. Greb in
`
`19· · · · preparation for your deposition?
`
`20· ·A· · Just to look over this document, that's about it.
`
`21· · · · Prep me for any questions that you may ask.
`
`22· ·Q· · What kind of questions were suggested?
`
`23· · · · · · · · · MS. GREB:· I would just remind the witness
`
`24· · · · not to reveal the contents of any attorney/client
`
`25· · · · privileged information that may have been discussed
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 5
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`6
`
`·1· · · · during her meeting with her counsel.
`
`·2· ·BY MR. FELDSTEIN, CONTINUING:
`
`·3· ·Q· · Maybe I should back up a step.· Is Ms. Ellingstad
`
`·4· · · · your attorney here?
`
`·5· ·A· · Yes.
`
`·6· ·Q· · Is Ms. Greb your attorney here?
`
`·7· ·A· · No.
`
`·8· ·Q· · So what discussions did you have with Ms. Greb
`
`·9· · · · regarding -- in preparation?
`
`10· ·A· · What discussions, just about the documents
`
`11· · · · themselves and what my role is here today.
`
`12· ·Q· · And what were you told about your role?
`
`13· ·A· · What was I told?
`
`14· ·Q· · Yes.
`
`15· ·A· · I wasn't told anything -- well, I just knew I was
`
`16· · · · talking about these documents.· The role was my role
`
`17· · · · in the company as she had asked, and we had talked
`
`18· · · · about what my history was and my role.
`
`19· ·Q· · Did you discuss with Ms. Greb the substance of your
`
`20· · · · declaration?
`
`21· · · · · · · · · MS. GREB:· Object to form.
`
`22· ·A· · Did I -- can you repeat that.
`
`23· ·BY MR. FELDSTEIN, CONTINUING:
`
`24· ·Q· · Sure.· Did you discuss the substance of your
`
`25· · · · declaration with Ms. Greb in preparation for your
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 6
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`7
`
`·1· · · · deposition today?
`
`·2· · · · · · · · · MS. GREB:· Object to form.
`
`·3· ·BY MR. FELDSTEIN, CONTINUING:
`
`·4· ·Q· · You can answer.
`
`·5· ·A· · Yes.
`
`·6· ·Q· · What did you discuss with Ms. Greb about the
`
`·7· · · · substance of your declaration?
`
`·8· · · · · · · · · MS. GREB:· Object to form.
`
`·9· ·A· · The content which I provided in the declaration, so
`
`10· · · · we just went over what I had stated in here.
`
`11· ·BY MR. FELDSTEIN, CONTINUING:
`
`12· ·Q· · Did you discuss anything beyond what's literally in
`
`13· · · · the declaration?
`
`14· · · · · · · · · MS. GREB:· Object to form.
`
`15· ·A· · No.
`
`16· ·BY MR. FELDSTEIN, CONTINUING:
`
`17· ·Q· · Had you discussed the declaration with anyone, any
`
`18· · · · counsel from Mylan prior to completing the
`
`19· · · · declaration?
`
`20· ·A· · No.
`
`21· ·Q· · How do you come to be the author of the declaration,
`
`22· · · · Exhibit 1055?
`
`23· ·A· · Well, I worked in news and I'm in charge of the
`
`24· · · · content.· So the general counsel here at Thompson
`
`25· · · · sends me the title of documents and I provide the
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 7
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`8
`
`·1· · · · information about them that I can.
`
`·2· ·Q· · And so that's how you became involved in preparing
`
`·3· · · · Exhibit 1055, the general counsel sent you the
`
`·4· · · · documents listed in paragraph 6 A, B and C?
`
`·5· · · · · · · · · MS. GREB:· Object to form.
`
`·6· ·A· · Yes.· I just receive the title of the documents and
`
`·7· · · · the date.
`
`·8· ·BY MR. FELDSTEIN, CONTINUING:
`
`·9· ·Q· · And what were you asked to do with the title and the
`
`10· · · · date?
`
`11· ·A· · I was asked to --
`
`12· · · · · · · · · MS. GREB:· Object to form, and I don't
`
`13· · · · know what the general counsel's role was in any of
`
`14· · · · this, but to the extent there was any
`
`15· · · · attorney/client privileged information or the
`
`16· · · · general counsel was acting as a lawyer I would
`
`17· · · · caution you not to reveal the contents of those
`
`18· · · · conversations.
`
`19· · · · · · · · · MS. ELLINGSTAD:· Can I confer with my
`
`20· · · · client for just one second?
`
`21· · · · · · · · · MR. FELDSTEIN:· Absolutely.
`
`22· · · · · · · · · (WHEREUPON, a brief recess was taken at
`
`23· · · · this time.)
`
`24· ·BY MR. FELDSTEIN, CONTINUING:
`
`25· ·Q· · So, Ms. Rock, I should say that if you have any
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 8
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`9
`
`·1· · · · questions about privilege you're welcome to break
`
`·2· · · · any time you need to to talk to Ms. Ellingstad.
`
`·3· ·A· · Thank you.
`
`·4· · · · · · · · · MR. FELDSTEIN:· Could you read back my
`
`·5· · · · question, please.
`
`·6· · · · · · · · · (WHEREUPON, the requested portion was read
`
`·7· · · · back.)
`
`·8· ·A· · Provide the date and time the content was made
`
`·9· · · · available in Westlaw.
`
`10· ·BY MR. FELDSTEIN, CONTINUING:
`
`11· ·Q· · Were you asked to do anything else?
`
`12· ·A· · No.
`
`13· ·Q· · And then when were you -- when did this request come
`
`14· · · · to you regarding the documents identified in
`
`15· · · · paragraph 6 A, B and C of Exhibit 1055?
`
`16· · · · · · · · · MS. GREB:· Object to form.
`
`17· ·A· · Originally, in the original e-signed document, in
`
`18· · · · July and then secondary in February.
`
`19· ·BY MR. FELDSTEIN, CONTINUING:
`
`20· ·Q· · July of 2018?
`
`21· ·A· · Yes.
`
`22· ·Q· · And the request came to you in July of 2018?
`
`23· ·A· · Yes.
`
`24· ·Q· · And then you completed the declaration also in July
`
`25· · · · of 2018?
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 9
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`10
`
`·1· ·A· · Correct.
`
`·2· ·Q· · Who actually prepared the declaration itself, do you
`
`·3· · · · know?
`
`·4· · · · · · · · · MS. GREB:· Object to form.
`
`·5· ·A· · Brian Behrs.
`
`·6· ·BY MR. FELDSTEIN, CONTINUING:
`
`·7· ·Q· · Who is he?
`
`·8· ·A· · He is the licensing -- if I can get the word out --
`
`·9· · · · licensing manager for news contracts.
`
`10· ·Q· · Backing up a little bit to your preparation for
`
`11· · · · today, how long did you meet with Ms. Greb?
`
`12· ·A· · Oh, less than 30 minutes.
`
`13· ·Q· · So if we could start right at the top of Exhibit
`
`14· · · · 1055, you say you've been employed by West
`
`15· · · · Publishing Corporation in the area which acquires
`
`16· · · · news articles for inclusion Westlaw for 13 years.
`
`17· · · · Can you just start -- tell us when you actually
`
`18· · · · first started at West?
`
`19· ·A· · I actually started in April of 1990.
`
`20· ·Q· · And 13 years ago did you take some new position?
`
`21· ·A· · That's how long I had been in this role when I
`
`22· · · · originally -- yes.
`
`23· ·Q· · 13 years from July 2018?
`
`24· ·A· · Yes.
`
`25· ·Q· · And what is your role as of roughly July 2005?
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 10
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`11
`
`·1· ·A· · July 2005 it was actually the same, pretty much the
`
`·2· · · · same role.· I've just gotten added duties but I did
`
`·3· · · · work with the newsroom content.
`
`·4· ·Q· · So what was your position in July 2005?
`
`·5· ·A· · It was called content analyst.
`
`·6· ·Q· · What did you do as content analyst?
`
`·7· ·A· · I maintain all of the news publications on Westlaw
`
`·8· · · · and I make sure the content gets online, and then I
`
`·9· · · · also work to get any new content online from
`
`10· · · · different providers and news locations.
`
`11· ·Q· · And high level, I don't want to go year by year, but
`
`12· · · · high level between 1990 and 2005 roughly what were
`
`13· · · · you doing at West?
`
`14· ·A· · I was maintaining internal systems.
`
`15· ·Q· · Do you have some sort of computer background at all?
`
`16· ·A· · No.
`
`17· ·Q· · What kind of educational background do you have?
`
`18· ·A· · High school, some college.
`
`19· ·Q· · So maintaining means what, it's not maintaining the
`
`20· · · · computer systems it's maintaining something else?
`
`21· ·A· · Maintaining internal systems with information, the
`
`22· · · · core of Westlaw.
`
`23· ·Q· · The cases and such?
`
`24· ·A· · Well, making sure that they're displayable and work
`
`25· · · · for the customers.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 11
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`12
`
`·1· ·Q· · And then around July 2005 you switched in to doing
`
`·2· · · · that same sort of maintaining of content but in the
`
`·3· · · · news area?
`
`·4· ·A· · In a more specific role.
`
`·5· ·Q· · Since July 2005 your position has been roughly the
`
`·6· · · · same but with more responsibilities?
`
`·7· ·A· · Yes.
`
`·8· ·Q· · And was it truly July of 2005 when you started in
`
`·9· · · · the area which requires news articles?
`
`10· ·A· · In this role, yes, about -- it was actually probably
`
`11· · · · March of 2005.
`
`12· ·Q· · In the 13 years that you've been in the -- well, let
`
`13· · · · me try and get a question.· Is there a name for the
`
`14· · · · group you're in now, just so we can talk about it?
`
`15· ·A· · The group I'm in?
`
`16· ·Q· · Yes.
`
`17· ·A· · Specialty content.
`
`18· ·Q· · That's the news?
`
`19· ·A· · News and public record area.
`
`20· ·Q· · Has that -- has the news and public records area,
`
`21· · · · the content they control, changed over the last 13
`
`22· · · · years?
`
`23· ·A· · No.
`
`24· ·Q· · Have the ways in which the news and public records
`
`25· · · · maintained by your group -- strike that.· Has the
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 12
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`13
`
`·1· · · · way in which users access information maintained by
`
`·2· · · · the news and public records group changed over the
`
`·3· · · · last 13 years?
`
`·4· ·A· · Not for news.
`
`·5· ·Q· · What's your current title?
`
`·6· ·A· · I go by content analyst, but I believe it's senior
`
`·7· · · · data base specialist.· The roles change quite often
`
`·8· · · · here.
`
`·9· ·Q· · The roles or the titles?
`
`10· ·A· · Well, job titles.
`
`11· ·Q· · Let me skip down to paragraph 3 of Exhibit 1055.
`
`12· · · · You say West obtains news articles under license
`
`13· · · · from Business Wire for inclusion on Westlaw to
`
`14· · · · permit authorized subscribers to access these
`
`15· · · · articles.· I just want to get some more information
`
`16· · · · on each of these point.· The license that you
`
`17· · · · reference, do you have an understanding of the terms
`
`18· · · · of that license?
`
`19· ·A· · Yes.
`
`20· ·Q· · When did that license become effective, do you know?
`
`21· · · · · · · · · MS. GREB:· Object to form.
`
`22· ·A· · I do not.
`
`23· ·BY MR. FELDSTEIN, CONTINUING:
`
`24· ·Q· · Do you know what if any limitations there are within
`
`25· · · · the license on how Westlaw can use information
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 13
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`14
`
`·1· · · · obtained from Business Wire?
`
`·2· · · · · · · · · MS. GREB:· Object to form.
`
`·3· ·A· · I do not.
`
`·4· ·BY MR. FELDSTEIN, CONTINUING:
`
`·5· ·Q· · Generally speaking, what terms of license are you
`
`·6· · · · aware of?
`
`·7· ·A· · What terms of the license?· The availability that we
`
`·8· · · · can provide to customers and the times -- or our
`
`·9· · · · process times.
`
`10· ·Q· · What do you mean with respect to availability of
`
`11· · · · customers?
`
`12· ·A· · The fact that we'll get the content online as soon
`
`13· · · · as we can after we convert it.
`
`14· ·Q· · That's part of the license?
`
`15· ·A· · Yes.
`
`16· ·Q· · What do you mean convert it?
`
`17· ·A· · Convert it is where we pull out -- how do I word
`
`18· · · · this -- we pull out standardized fields and put them
`
`19· · · · in the form of a document on Westlaw.
`
`20· ·Q· · I suppose I should actually back up, and this would
`
`21· · · · be good opportunity to do it, can you describe
`
`22· · · · generally what Westlaw is?
`
`23· ·A· · Westlaw is a online --
`
`24· · · · · · · · · MS. GREB:· Object to form.
`
`25· ·A· · It's a online information database.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 14
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`15
`
`·1· ·BY MR. FELDSTEIN, CONTINUING:
`
`·2· ·Q· · Is it a pay service?
`
`·3· ·A· · Yes.
`
`·4· ·Q· · Who primarily is it directed to?
`
`·5· · · · · · · · · MS. GREB:· Object to form.
`
`·6· ·A· · It's primarily for -- originally it was for lawyers.
`
`·7· ·BY MR. FELDSTEIN, CONTINUING:
`
`·8· ·Q· · Have the terms of the license, to your knowledge,
`
`·9· · · · changed over the last I guess 14 years now?
`
`10· · · · · · · · · MS. GREB:· Object to form.
`
`11· ·A· · I cannot definitely answer that, but I would say --
`
`12· · · · I don't know.
`
`13· ·BY MR. FELDSTEIN, CONTINUING:
`
`14· ·Q· · Okay.· Has the scope of the content you receive from
`
`15· · · · Business Wire changed over 14 years?
`
`16· · · · · · · · · MS. GREB:· Object to form.
`
`17· ·A· · What do you mean by scope?
`
`18· ·BY MR. FELDSTEIN, CONTINUING:
`
`19· ·Q· · What do you receive from Business Wire?
`
`20· ·A· · A text file of -- a text file in document form where
`
`21· · · · we pull out specific parts of the document itself.
`
`22· ·Q· · Do you receive all text files that Business Wire
`
`23· · · · creates or only some subset of text files that
`
`24· · · · Business Wire creates?
`
`25· ·A· · We receive them all.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 15
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`16
`
`·1· · · · · · · · · MS. GREB:· Object to form.
`
`·2· ·BY MR. FELDSTEIN, CONTINUING:
`
`·3· ·Q· · Has that scope changed over time at all, to your
`
`·4· · · · knowledge?
`
`·5· ·A· · No.
`
`·6· ·Q· · So you refer in paragraph 3 to authorized
`
`·7· · · · subscribers and then in paragraph 6 you also refer
`
`·8· · · · to authorized Westlaw subscribers.· Is that the same
`
`·9· · · · subscribers in both?
`
`10· ·A· · No.· There's different forms of subscribers.
`
`11· ·Q· · So authorized subscriber in paragraph 3 is not
`
`12· · · · necessarily the same as an authorized Westlaw
`
`13· · · · subscriber in paragraph 6?
`
`14· ·A· · They are not the same.
`
`15· ·Q· · So what's the authorized subscriber that you
`
`16· · · · described in paragraph 3?
`
`17· ·A· · That's for any user interface that we are allowed to
`
`18· · · · display the Business Wire content.· Thompson Reuters
`
`19· · · · owns many user interfaces where the Business Wire is
`
`20· · · · located.
`
`21· ·Q· · So is an authorized Thompson Reuter subscriber in
`
`22· · · · paragraph 3 sort of a broader category?
`
`23· ·A· · Yes.
`
`24· ·Q· · And then the authorized Westlaw subscribers in
`
`25· · · · paragraph 6, can you explain any further what that
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 16
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`17
`
`·1· · · · is or who they are?
`
`·2· ·A· · That's for specifically the URL that Westlaw is
`
`·3· · · · dedicated to.· So that's that specific group of
`
`·4· · · · content that this (indicating) is, these documents
`
`·5· · · · describe.
`
`·6· ·Q· · And the ones listed on Exhibit 1055?
`
`·7· ·A· · Yes.
`
`·8· ·Q· · So what does it mean to be an authorized Westlaw
`
`·9· · · · subscriber?
`
`10· · · · · · · · · MS. GREB:· Object to form.
`
`11· ·A· · That means you actually have a paid account with
`
`12· · · · Thompson Reuters to access the URL webside.
`
`13· ·BY MR. FELDSTEIN, CONTINUING:
`
`14· ·Q· · A paid account with Thompson Reuters to access
`
`15· · · · Westlaw?
`
`16· ·A· · Yes.
`
`17· ·Q· · Are you aware of the cost of obtaining a paid
`
`18· · · · account with Thompson Reuters to access Westlaw?
`
`19· ·A· · No.
`
`20· ·Q· · I take it you don't know what it is now?
`
`21· ·A· · No, there's no straight line.
`
`22· ·Q· · I'm just going to go over the chronology.· You also
`
`23· · · · don't know what it was back around 2005?
`
`24· ·A· · No.
`
`25· ·Q· · So an authorized Westlaw subscriber -- well, that's
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 17
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`18
`
`·1· · · · fine.· Let's start again.· Is there just one class
`
`·2· · · · of authorized Westlaw subscribers or are there
`
`·3· · · · different categories of authorized Westlaw
`
`·4· · · · subscribers, in terms of the information they can
`
`·5· · · · access?
`
`·6· ·A· · There's different categories.
`
`·7· ·Q· · What different categories are there?
`
`·8· ·A· · It all depends on what the customer subscribes for.
`
`·9· ·Q· · What are the options or just generally to your
`
`10· · · · knowledge what different options can a customer
`
`11· · · · subscribe to Westlaw for?
`
`12· ·A· · Different content types.· We have multiple types of
`
`13· · · · content, cases, codes and statutes, news, public
`
`14· · · · records, which is much stricter.· That's not open to
`
`15· · · · the regular public.
`
`16· ·Q· · Which is not open to the general public?
`
`17· ·A· · Public records.
`
`18· ·Q· · And so depending on what type of subscription you
`
`19· · · · have to Westlaw dictates what databases you can
`
`20· · · · access?
`
`21· ·A· · Yes.
`
`22· ·Q· · I may not be using the term totally correctly but is
`
`23· · · · pay wall a term you're familiar with?
`
`24· ·A· · Yes.
`
`25· · · · · · · · · MS. GREB:· Object to form.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 18
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`19
`
`·1· ·BY MR. FELDSTEIN, CONTINUING:
`
`·2· ·Q· · Does Westlaw affect -- well, what do you understand
`
`·3· · · · pay wall to be?
`
`·4· ·A· · A pay wall is actually a page that you have to get
`
`·5· · · · through by a unique identifier or user name in order
`
`·6· · · · to access where you're going on the internet.
`
`·7· ·Q· · Is Westlaw set up with a pay wall to prevent
`
`·8· · · · unauthorized access?
`
`·9· · · · · · · · · MS. GREB:· Object to form.
`
`10· ·A· · Yes.
`
`11· ·BY MR. FELDSTEIN, CONTINUING:
`
`12· ·Q· · So you can't get to Westlaw results just from
`
`13· · · · Google, for example?
`
`14· ·A· · No.
`
`15· ·Q· · No, you can't?
`
`16· ·A· · No, you can't.
`
`17· ·Q· · Thanks.· So paragraph 4 of Exhibit 1055, you say
`
`18· · · · that West includes the text of the news articles on
`
`19· · · · Westlaw as they are received from Business Wire;
`
`20· · · · right?
`
`21· ·A· · Yes.
`
`22· ·Q· · You take the text and you add some additional
`
`23· · · · information on top of that; is that correct?
`
`24· · · · · · · · · MS. GREB:· Object to form.
`
`25· ·A· · We don't add it on top of it, we add it in addition
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 19
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`20
`
`·1· · · · to what they give us.
`
`·2· ·BY MR. FELDSTEIN, CONTINUING:
`
`·3· ·Q· · Actually I'm not sure what the difference is between
`
`·4· · · · on top of and in addition.
`
`·5· ·A· · Do you want my definition?
`
`·6· ·Q· · Yes.
`
`·7· ·A· · On top of would mean that we insert information
`
`·8· · · · within a document after it's received, and we add to
`
`·9· · · · it by adding extra at the end of the document for
`
`10· · · · searching purposes.
`
`11· ·Q· · So take a look at Exhibit 1026 as an example.· Can
`
`12· · · · you identify what Westlaw added on top of what it
`
`13· · · · obtained from Business Wire?
`
`14· · · · · · · · · MS. GREB:· Object on form.
`
`15· ·A· · Anything after where it says index references.
`
`16· ·BY MR. FELDSTEIN, CONTINUING:
`
`17· ·Q· · And actually I want to fix that, because I used the
`
`18· · · · wrong word.· You say you added things in addition
`
`19· · · · to; right?
`
`20· ·A· · Yes.
`
`21· ·Q· · So let me ask the question again.· In using Exhibit
`
`22· · · · 2016 as an example, can you identify what
`
`23· · · · information Westlaw added in addition to what it got
`
`24· · · · from Business Wire?
`
`25· ·A· · The information below -- underneath index
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 20
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`21
`
`·1· · · · references.
`
`·2· ·Q· · I'm sorry, what page are you looking at?
`
`·3· ·A· · That would be on page two.
`
`·4· ·Q· · I see.· And I take it that the footer that says
`
`·5· · · · Westlaw, and it's hard to read, but 2018, that's
`
`·6· · · · something that's added in addition by Westlaw?
`
`·7· ·A· · Where are you looking?
`
`·8· ·Q· · It's kind of hard to see, but there's a horizontal
`
`·9· · · · bar.
`
`10· ·A· · Oh, yup.· That is part of our printing -- that's
`
`11· · · · part of our print format, it's not on the document
`
`12· · · · itself.· So when the document prints it's added as a
`
`13· · · · footer.
`
`14· ·Q· · And the footer is live updated with prints?
`
`15· · · · · · · · · MS. GREB:· Object to form.
`
`16· ·A· · Yes, as it's printed off.
`
`17· ·BY MR. FELDSTEIN, CONTINUING:
`
`18· ·Q· · So if we printed in 2018 Exhibit 1026 it would say
`
`19· · · · Westlaw copyright 2018?
`
`20· ·A· · Yes.
`
`21· ·Q· · And if we printed it this year in 2019, it would say
`
`22· · · · Westlaw copyright 2019?
`
`23· ·A· · Yes.
`
`24· ·Q· · And at the top of Exhibit 1026, are any of the text
`
`25· · · · in the top quarter of Exhibit 1026 something that
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 21
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`22
`
`·1· · · · Westlaw added in addition to what it got from
`
`·2· · · · Business Wire?
`
`·3· · · · · · · · · MS. GREB:· Object to form.
`
`·4· ·A· · In addition to the title itself.· So the second
`
`·5· · · · line, the newsroom header, upper right hand corner,
`
`·6· · · · where it actually says Business Wire right above the
`
`·7· · · · copyright, that is an internal system that displays
`
`·8· · · · that.
`
`·9· ·BY MR. FELDSTEIN, CONTINUING:
`
`10· ·Q· · And your understanding is that the content, other
`
`11· · · · than the things that you've identified as being
`
`12· · · · added in addition by Westlaw, the content of Exhibit
`
`13· · · · 1026 otherwise came from Business Wire?
`
`14· ·A· · Yes.
`
`15· ·Q· · And would that be true for Exhibit 1005 and 1016
`
`16· · · · too?· That other than the things you've identified
`
`17· · · · all the content, to your understanding, comes from
`
`18· · · · Business Wire?
`
`19· ·A· · Yes.
`
`20· ·Q· · So can you explain, using again Exhibit 1026 as an
`
`21· · · · example, how you got to the document from
`
`22· · · · information provided to you by the Thompson Reuters
`
`23· · · · general counsel?
`
`24· · · · · · · · · MS. GREB:· Objection to form, and I would
`
`25· · · · remind the witness not to reveal any attorney/client
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 22
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`23
`
`·1· · · · privileged information and if she has any questions
`
`·2· · · · to talk to her client outside of the room.
`
`·3· ·A· · Is there a way you can say that differently?
`
`·4· ·BY MR. FELDSTEIN, CONTINUING:
`
`·5· ·Q· · I want to know what steps you took to actually find
`
`·6· · · · Exhibit 1026 after having been given the title and
`
`·7· · · · date of -- well, let me back up.· You were given, in
`
`·8· · · · July 2018 you were given the title and date of
`
`·9· · · · Exhibit 1026; correct?
`
`10· ·A· · Yes.
`
`11· ·Q· · And that date being April 7th, 2005; correct?
`
`12· ·A· · Yes.
`
`13· ·Q· · And the title being what begins BG-12 Psoriasis
`
`14· · · · Study?
`
`15· ·A· · Yes.
`
`16· ·Q· · With that information, how did you go about
`
`17· · · · obtaining Exhibit 1026?
`
`18· · · · · · · · · MS. GREB:· Object to form.
`
`19· ·A· · How did I obtain it?· I actually did a internal
`
`20· · · · search in the database.
`
`21· ·BY MR. FELDSTEIN, CONTINUING:
`
`22· ·Q· · Can you walk us through what that internal search
`
`23· · · · entailed?
`
`24· ·A· · I just actually typed the title and the date in the
`
`25· · · · open box on Westlaw and retrieved the document.
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`EsquireSolutions.comYVer1f
`
`MYLAN PHARMS. INC. EXHIBIT 1059 PAGE 23
`
`
`
`JENNIFER ROCK
`JENNIFER ROCK
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`MYLAN PHARMACEUTICALS vs BIOGEN MA
`
`May 02, 2019
`May 02, 2019
`24
`
`·1· ·Q· · In to -- what is it, open box?
`
`·2· ·A· · The entry field -- I don't know the word for it
`
`·3· · · · right now.· The query box.
`
`·4· ·Q· · Was that just the -- when I open Westlaw I get sort
`
`·5· · · · of a generic query box, is that where you typed it
`
`·6· · · · or do you have to go to some sub database to put in
`
`·7· · · · the title and date?
`
`·8· · · · · · · · · MS. GREB:· Object to form.
`
`·9· ·A· · I have to go in to another part where it says news.
`
`10· · · · So the exact steps would be I'd sign on to Westlaw
`
`11· · · · and I'd click on the news header and then I'd do the
`
`12· · · · date and title search.
`
`13· ·BY MR. FELDSTEIN, CONTINUING:
`
`14· ·Q· · And do you put the title in as key words or just the
`
`15· · · · whole title with quotes or something?
`
`16· ·A· · Key words.
`
`17· ·Q· · And did you put the whole title in here to get this
`
`18· · · · document 1026 or did you use select words from the
`
`19· · · · title?
`
`20· · · · · · · · · MS. GREB:· Object to form.
`
`21· ·A· · If you look, the BG-12 is highlighted, that's what
`
`22· · · · was searched for.
`
`23· ·BY MR. FELDSTEIN, CONTINUING:
`
`24· ·Q· · And the date is not highlighted, so you didn't
`
`25· · · · search on date?
`
`800.211.DEPO (3376)
`800.211.DEPO (3376)
`EsquireSolutions.com
`Esquire
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
